Predicate |
Object |
assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_2ca2e4410855da087e11bf3eea8933fa |
classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P5-26 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P13-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P15-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P15-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P21-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-403 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P19-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P19-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P21-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-405 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D401-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D209-58 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D209-60 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D209-94 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4439 |
classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4439 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D401-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P5-26 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P43-00 |
filingDate |
2019-01-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5ce859f547f76bcabb0e44385600dedc http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5782fdd0a96ad93ccb591d9ca159c37d http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b32e55f925db5d43c509ebd7c56a0fc2 |
publicationDate |
2019-06-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber |
JP-2019089795-A |
titleOfInvention |
Treatment of androgen ablation therapy concomitant symptoms |
abstract |
The present invention provides a method for producing a compound used for the treatment of symptoms associated with androgen deprivation therapy, and a method for the treatment. As a result of secondary hypogonadism induced by androgen deprivation therapy comprising administering an effective amount of Formula I or a pharmaceutically acceptable salt thereof to a patient in need of such treatment. How to treat symptoms. [Selection figure] None |
priorityDate |
2014-09-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type |
http://data.epo.org/linked-data/def/patent/Publication |